Clinical Trial Goal
To find out:
- The highest dose of GLB-001-01 that's safe to give
- If GLB-001-01 is safe and works well to treat AML or MDS that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have AML or MDS that has relapsed or is refractory
- Do not have acute promyelocytic leukemia
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
GLB-001-01 is a protein degrader that targets CK1a in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- GLB-001-01 – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved GLB-001-01.
Locations
Sponsors
lead: GluBio Therapeutics Inc.
